LGVN

Longeveron Inc.
CAPPED RATING

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc. (LGVN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B
Factor Score 3.3 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.9
EV / EBITDA 0.0
Rev Growth YoY -9.2%
Gross Margin 69.8%
Price Return 3M -59.9%
Price Return 12M -58.6%
Catalyst Signal 0.00
Market Cap $9.5M
TTM Revenue $1.2M
Price / Sales 8.0
ROE -203.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B (3.3) C (2.2) B- (2.9) F (0.6) C+ (2.6) C (2.3)
2026-11-06 B (3.4) C (2.2) B- (2.9) F (0.5) C+ (2.7) C (2.3)
2026-10-30 B (3.3) B (3.3) B (3.3) F (0.5) C+ (2.7) C+ (2.6)
2026-10-23 B (3.3) B (3.3) B (3.3) F (0.5) C+ (2.6) C+ (2.6)
2026-10-16 B (3.4) B (3.3) B (3.3) D- (1.1) C+ (2.6) C+ (2.7)
Page 1 of 6